The GH-IGF-1 axis (also called the somatotropic axis) is the hypothalamic-pituitary growth hormone signaling cascade that regulates somatic growth, body composition, tissue repair, and metabolic homeostasis throughout life. Growth hormone-releasing hormone (GHRH) from the Hypothalamus stimulates somatotroph cells in the anterior pituitary gland to secrete Growth hormone (GH) in a pulsatile fashion, which then acts on the Liver and peripheral tissues to stimulate production of IGF-1 (insulin-like growth factor 1). Somatostatin from the hypothalamus provides tonic inhibition of GH release, while Ghrelin from the stomach provides an additional stimulatory input, linking nutritional status to growth signaling.
From a cPNI perspective, the GH-IGF-1 axis embodies one of the most fundamental evolutionary trade-offs in biology: the balance between growth/reproduction and longevity/maintenance. IGF-1 signaling activates mTOR (mechanistic target of rapamycin), which drives protein synthesis, cell proliferation, and anabolic metabolism -- processes essential for development, wound healing, and muscle maintenance, but also implicated in accelerated aging and Cancer when chronically elevated. Conversely, reduced IGF-1 signaling activates AMPK, autophagy, and FOXO transcription factors -- the cellular maintenance and repair programs associated with extended life expectancy across species from worms to primates. Understanding this axis is therefore central to the cPNI approach to longevity, sarcopenia, Cancer prevention, and metabolic optimization.
The axis is profoundly influenced by lifestyle factors that cPNI practitioners can modulate: sleep quality determines GH pulse amplitude, Intermittent fasting powerfully stimulates GH while suppressing IGF-1, resistance training triggers acute GH release for tissue repair, and chronic inflammation and Cortisol excess suppress the entire axis. The GH-IGF-1 axis is also deeply immunomodulatory -- GH and IGF-1 support thymic function, lymphocyte proliferation, and immune reconstitution -- making it a key mediator in the neuro-endocrine-immune triad that defines psychoneuroimmunology.
GH secretion is governed by the interplay of three primary regulators at the hypothalamic level. GHRH (growth hormone-releasing hormone), produced by neurons in the arcuate and ventromedial nuclei of the Hypothalamus, is the principal stimulatory signal. GHRH binds to GHRH receptors on somatotroph cells, activating the Gs-adenylyl cyclase-cAMP-PKA pathway, which promotes both GH synthesis and secretion. Somatostatin (SST, also called growth hormone-inhibiting hormone or GHIH), produced by neurons in the periventricular nucleus, provides tonic inhibitory tone. SST binds to SSTR2 and SSTR5 receptors on somatotrophs, inhibiting cAMP production and directly suppressing GH release. The alternating pulses of GHRH stimulation and somatostatin withdrawal create the characteristic pulsatile pattern of GH secretion -- typically 6-12 pulses per 24 hours, with the largest pulse occurring during the first period of slow-wave sleep (SWS, NREM stages 3-4).
Ghrelin, the orexigenic hormone produced by P/D1 cells in the gastric fundus, acts as a potent GH secretagogue by binding to the growth hormone secretagogue receptor (GHSR-1a) on somatotrophs. Ghrelin's GH-stimulating effect is synergistic with GHRH and explains why GH secretion is powerfully linked to nutritional status: fasting increases ghrelin, which increases GH, which mobilizes fat stores -- an elegant adaptive mechanism for surviving periods of food scarcity. This is why Intermittent fasting can increase GH secretion by 300-500%, primarily through the ghrelin-GHSR axis combined with reduced Insulin (which normally suppresses GH).
GH is secreted from somatotroph cells (comprising approximately 50% of anterior pituitary cells) in a highly pulsatile manner. The pulsatile pattern is not merely a quirk of physiology -- it is functionally critical. GH receptors undergo rapid desensitization after sustained GH exposure, meaning that continuous GH delivery produces progressively weaker signaling. Pulsatile release, by contrast, allows receptor resensitization between pulses and generates qualitatively different downstream signaling patterns compared to continuous exposure. Clinically, this means that conditions disrupting GH pulsatility (such as obesity, chronic stress, or Hypercortisolaemia) impair GH signaling even if total 24-hour GH production appears adequate.
The largest GH pulse -- accounting for 70-80% of daily GH output -- occurs during the first episode of slow-wave sleep, typically within the first 90 minutes of sleep onset. This GH pulse is so tightly coupled to NREM stage 3-4 sleep that disruption of slow-wave sleep (by noise, alcohol, benzodiazepines, or sleep apnea) proportionally reduces GH secretion. A single night of sleep deprivation can reduce GH secretion by 70-80%. This link between sleep architecture and GH explains much of the catabolic physiology seen in chronic sleep disruption: impaired wound healing, accelerated sarcopenia, reduced immune surveillance, and metabolic dysfunction. In cPNI practice, optimizing sleep quality is therefore one of the most powerful interventions for supporting the GH-IGF-1 axis.
At the cellular level, GH binds to the growth hormone receptor (GHR), a type I cytokine receptor that exists as a preformed dimer on the cell surface. GH binding induces a conformational change that activates the receptor-associated JAK2 kinase. Activated JAK2 phosphorylates both the GHR intracellular domains and itself, creating docking sites for signaling molecules. The primary downstream pathway is JAK2-STAT5b, where STAT5b dimerizes, translocates to the nucleus, and activates transcription of GH-responsive genes including IGF-1, acid-labile subunit (ALS), and IGFBP-3 (the main IGF-1 binding protein). GH also activates the MAPK/ERK pathway (promoting cell proliferation) and the PI3K-Akt signaling pathway (promoting survival and metabolic effects).
Negative regulation occurs via SOCS proteins (particularly SOCS2 and SOCS3), which are themselves induced by GH signaling, creating a classical negative feedback loop. Inflammatory cytokines -- particularly IL-6 and TNF-α -- induce SOCS3 independently of GH, which then suppresses GH signaling. This is one mechanism by which chronic inflammation creates GH resistance: the liver "sees" sufficient GH but cannot respond because SOCS3 is blocking the JAK2-STAT5b pathway. This inflammation-induced GH resistance reduces hepatic IGF-1 production and contributes to the catabolic state seen in chronic inflammatory conditions, sepsis, and chronic fatigue syndrome.
IGF-1 is a 70-amino acid peptide hormone produced primarily by the Liver (approximately 75% of circulating IGF-1) in direct response to GH stimulation, with additional autocrine/paracrine production in muscle, bone, and other tissues. Circulating IGF-1 is almost entirely bound to IGF binding proteins (IGFBPs), of which there are six (IGFBP-1 through IGFBP-6). The dominant complex in serum is the ternary complex of IGF-1 + IGFBP-3 + acid-labile subunit (ALS), which extends IGF-1's half-life from approximately 10 minutes (free) to 12-16 hours (bound), creating a stable circulating reservoir. IGFBP bioavailability is regulated by specific proteases, Insulin, and nutritional status -- fasting reduces IGFBP-3 and increases IGFBP-1, shifting the balance toward less bioavailable IGF-1.
IGF-1 signals through the IGF-1 receptor (IGF-1R), a heterotetrameric Tyrosine kinase receptor structurally similar to the Insulin receptor. Upon ligand binding, the IGF-1R autophosphorylates and activates two major downstream cascades: (1) the PI3K-Akt signaling pathway, which promotes glucose uptake, protein synthesis (via mTOR), cell survival (via BAD/Bcl-2), and inhibits autophagy and FOXO-mediated gene transcription; and (2) the RAS-RAF-MEK-ERK (MAPK pathway) cascade, which drives cell proliferation and differentiation. The PI3K-Akt-mTOR branch is particularly significant in cPNI because it represents the molecular switch between growth mode and maintenance mode: high IGF-1 → PI3K → Akt → mTOR activation promotes anabolism but suppresses autophagy, DNA repair (FOXO-mediated), and longevity pathways, while low IGF-1 → reduced Akt → active FOXO + AMPK → autophagy and cellular housekeeping.
IGF-1 provides negative feedback at two levels: it acts directly on somatotroph cells to inhibit GH secretion, and it stimulates somatostatin release from the hypothalamus while inhibiting GHRH. This creates a classical endocrine negative feedback loop. However, the axis is also profoundly modulated by metabolic and inflammatory signals that can override this feedback:
The GH-IGF-1 axis is at the center of one of the most robust findings in aging biology: across multiple species -- from C. elegans to Drosophila to mice -- genetic or pharmacological reduction of GH/IGF-1 signaling extends lifespan, often dramatically. Ames dwarf mice (GH-deficient) live 60-70% longer than wild-type littermates. Laron syndrome patients (GH receptor deficiency, very low IGF-1) have near-zero rates of Cancer and Type 2 Diabetes despite high rates of obesity. These observations support the evolutionary medicine framework central to cPNI: in ancestral environments of intermittent food availability and high pathogen exposure, reduced IGF-1 signaling during fasting activated cellular repair and immune defense programs that promoted survival. In modern environments of caloric excess and chronic feeding, the axis is chronically activated, driving mTOR-dependent anabolic processes that accelerate aging, promote Cancer, and suppress autophagy.
The clinical implication for cPNI practice is that the goal is not to maximize or minimize IGF-1 but to restore the ancestral rhythmicity: periods of high IGF-1 (post-exercise, post-prandial, during sleep-associated GH pulses) for tissue repair and muscle maintenance, alternating with periods of low IGF-1 (during fasting, caloric restriction) for cellular housekeeping and autophagy. This is precisely the metabolic pattern achieved through Intermittent Living, time-restricted eating, and periodized resistance training.
GH secretion declines approximately 14% per decade after age 30 -- a phenomenon termed the "somatopause." By age 60, GH production is typically 25% of young-adult levels. This decline contributes to age-related loss of muscle mass (sarcopenia), increased visceral adiposity, bone density loss, thinning skin, reduced immune surveillance, and impaired wound healing. However, the somatopause is partly driven by modifiable factors rather than being an inevitable consequence of aging: obesity and insulin resistance suppress GH pulsatility, sleep disruption reduces nocturnal GH peaks, physical inactivity removes a major GH stimulus, and chronic inflammation induces hepatic GH resistance. This means that substantial restoration of GH-IGF-1 axis function is possible through lifestyle intervention -- a core principle of cPNI.
Resistance training is the most potent acute GH stimulus: high-volume, moderate-to-high intensity resistance exercise can increase GH secretion 10-fold or more in the 15-30 minutes post-exercise. This exercise-induced GH pulse, combined with post-exercise protein intake stimulating IGF-1, creates the anabolic window for muscle hypertrophy and connective tissue repair. In older adults, combining resistance training with adequate protein intake (1.2-1.6 g/kg/day), optimized sleep quality, and inflammatory resolution can substantially counteract sarcopenia and restore functional capacity.
GH and IGF-1 are potent immunomodulatory agents, connecting the somatotropic axis directly to immune function. The thymus expresses both GH receptors and IGF-1 receptors, and GH/IGF-1 signaling promotes thymic epithelial cell proliferation, T cell development, and thymopoiesis. Age-related thymic involution -- the progressive shrinking and fatty replacement of the thymus beginning in puberty -- is partly driven by declining GH/IGF-1 signaling and partly by increasing Cortisol (which is directly thymolytic). Studies in aged animals and humans have shown that GH administration can partially reverse thymic involution and restore naive T cell output, suggesting that the somatopause contributes to immunosenescence.
Beyond thymic effects, GH enhances NK cell activity, macrophage phagocytosis, and immunoglobulin production. IGF-1 promotes B cell and T cell proliferation and serves as a survival factor for lymphocytes. However, these immune-stimulating effects have a dark side: excessive IGF-1 signaling can promote survival of autoreactive lymphocytes and may contribute to autoimmune disease in susceptible individuals. The balance between immune support (requiring adequate GH/IGF-1) and immune regulation (requiring periods of reduced IGF-1 for autophagy of damaged immune cells) again points to the importance of rhythmic, pulsatile axis function rather than chronic activation or suppression.
Elevated circulating IGF-1 is associated with increased risk of breast, prostate, and colorectal cancers. The mechanism is straightforward: IGF-1 activates PI3K-Akt signaling and mTOR, promoting cell proliferation and inhibiting apoptosis -- both hallmarks of Cancer biology. IGF-1 also suppresses p53-mediated DNA damage responses and inhibits autophagy, reducing the cell's capacity for self-repair and quality control. Cancer cells frequently upregulate IGF-1 receptor expression, making them hypersensitive to circulating IGF-1. Dietary strategies that lower IGF-1 -- Intermittent fasting, protein restriction (especially animal protein), and caloric restriction -- are therefore relevant to Cancer prevention in cPNI practice. The target is not IGF-1 elimination but the restoration of fasting-feeding cycles that allow periodic IGF-1 suppression for cellular housekeeping.